ClearMed
BriefingsDrug & Biomarker IndexSaved (0)
All Gastroenterology BriefingsThe Lancet Gastroenterology & Hepatology
GastroenterologyPhase III3 min read

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, Phase 3, randomised, double-blind, placebo-controlled trial

Aspirin After Colon Cancer: A Surprising Setback for a Common Drug.

Published in The Lancet Gastroenterology & HepatologyRandomized controlled trial
5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Source
Gastroenterology editorial context for Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial
Gastroenterology · The Lancet Gastroenterology & HepatologyLEVEL 1 · Randomized controlled trial

Study Cohort

428 patients

Taking aspirin after surgery for colon cancer that spread to the liver did not prevent the cancer from returning and was linked to worse survival and more serious side effects.

What Changes?

Gastroenterology · Phase III

Current Standard

Conventional gastroenterology practice relies on standard-of-care monitoring and existing regimens prior to this .

New Finding

For patients who have undergone curative treatment for colorectal cancer that has spread to the liver, routine aspirin use is not recommended.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    While aspirin has shown promise in preventing and fighting colorectal cancer in other settings, its role after treating metastatic disease has been unclear.

  2. 02Study Evidence

    Tested in a (428 patients) at the Phase III stage.

  3. 03Practical Meaning

    This study suggests it might do more harm than good.

What This Means for You

For patients who have undergone curative treatment for colorectal cancer that has spread to the liver, routine aspirin use is not recommended. This study suggests it might do more harm than good.

The Discovery

Colorectal cancer often spreads to the liver, and even after successful treatment, the cancer frequently comes back. While aspirin has shown promise in preventing and fighting colorectal cancer in other settings, its role after treating metastatic disease has been unclear. This large study, involving 428 patients across Scandinavia, aimed to definitively answer whether daily aspirin could improve outcomes. The results, however, delivered an unexpected blow.

How It Works, Simply

This gastroenterology research focuses on mucosal barrier & gut modulation. Researchers evaluated it using a randomized controlled trial (428 patients) at the Phase III stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    While aspirin has shown promise in preventing and fighting colorectal cancer in other settings, its role after treating metastatic disease has been unclear.

  2. 02Study Evidence

    Tested in a (428 patients) at the Phase III stage.

  3. 03Practical Meaning

    This study suggests it might do more harm than good.

01

Biological Mechanism & Study Design

Study Design & Cohort

Randomized controlled trial

Randomized controlled trial (428 patients) · Phase III

Biological Pathway & Modality

Mucosal barrier & gut modulation

Intervention: Aspirin after curative-intent treatment of colorectal cancer liver metastases

02

Experimental Findings & Endpoints

Colorectal cancer often spreads to the liver, and even after successful treatment, the cancer frequently comes back.

While aspirin has shown promise in preventing and fighting colorectal cancer in other settings, its role after treating metastatic disease has been unclear. This large study, involving 428 patients across Scandinavia, aimed to definitively answer whether daily aspirin could improve outcomes.

The results, however, delivered an unexpected blow.

03

Clinical Translation & Practice Context

For patients who have undergone curative treatment for colorectal cancer that has spread to the liver, routine aspirin use is not recommended.

This study suggests it might do more harm than good.

03

The Bottom Line · Clinical Pearl

“Taking aspirin after surgery for colon cancer that spread to the liver did not prevent the cancer from returning and was linked to worse survival and more serious side effects.”

Published in The Lancet Gastroenterology & Hepatology · Current Stage: Phase III

Gastroenterology · Phase III
Study Type
Randomized controlled trial

Randomized controlled trial (428 patients)

Evidence Score
5/5 · Gold-Standard Human Evidence
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Who It Applies To
Randomized controlled trial (428 patients) in gastroenterology care
Intervention & Mechanism
Aspirin after curative-intent treatment of colorectal cancer liver metastases

Mucosal barrier & gut microbiome modulation

Key Limitation
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.

Translational Stage

LEVEL 1 · Phase III

Classified as Randomized controlled trial along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. 3Phase IIIActive
  4. 4Meta & Practice

Original Publication & AMA Citation

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology & Hepatology. Published 2026;Nov 15. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42777749/

The Lancet Gastroenterology & Hepatology

https://pubmed.ncbi.nlm.nih.gov/42777749/

Read Original Paper

Continue Reading

Related in Gastroenterology

View all Gastroenterology briefings →
GASTROENTEROLOGY · REAL-WORLD COHORT

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study

Silent Liver Damage: A Hidden Epidemic in China's Adult Population. Liver scarring and fatty liver disease are widespread among Chinese adults, largely fueled by metabolic issues and alcohol.

4/5 Strong Trial
Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readThe Lancet Gastroenterology & Hepatology
GASTROENTEROLOGY · REAL-WORLD COHORT

Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study

Unlocking the Genetic Link Between Liver Failure and Kidney Damage. Scientists have pinpointed a specific gene, SUSD1, that significantly increases the risk of kidney problems in people with severe liver disease.

5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & Hepatology
GASTROENTEROLOGY · CLINICAL PRACTICE

AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis

The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life. Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis (tissue scarring), cirrhosis, liver transplantation, and premature risk of death.

5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readGastroenterology